A New Era for Schizophrenia Management Chris Boerner, board chair and CEO of Bristol Myers Squibb, emphasised the importance of this development, describing it as a transformative moment in the field of schizophrenia treatment. He noted that Cobenfy's approval introduces an entirely new pharmacological approach, which has the potential to reshape the way schizophrenia is managed, especially given the limited advancements in treatment options over the past three decades. With the launch of Cobenfy. Bristol Myers Squibb aims to address the unmet needs in neuropsychiatry. starting with this breakthrough in schizophrenia care.